Peptide therapeutics and methods for using same

Patent metadata

Field	Value
Publication number	US-2018344814-A1
Application number	US-201715850092-A
Country	US
Kind code	A1
Filing date	Dec 21, 2017
Priority date	Dec 6, 2012
Publication date	Dec 6, 2018
Grant date	—

Abstract

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants or analogues of GLP-1, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2′6′-Dmt-Lys-Phe-NH 2 ).

First claim

What is claimed is:

1 . A composition comprising GLP-1 alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2′6′-Dmt-Lys-Phe-NH 2 ) or one or more aromatic-cationic peptides disclosed in section II or Table 1.

2 . The composition of claim 1 , further comprising one or more additional active agents such as cyclosporine, a cardiac drug, an anti-inflammatory, an anti-hypertensive drug, an antibody, an ophthalmic drug, an antioxidant, a metal complexer, and an antihistamine.

3 . A method for treating or preventing mitochondrial dysfunction in a subject, comprising administering to the subject a therapeutically effective amount of the composition of claim 1 .

4 . A method of treating a disease or condition characterized by mitochondrial dysfunction, comprising administering a therapeutically effective amount of the composition of claim 1 .

5 . The method of claim 4 , wherein the disease or condition comprises a neurological or neurodegenerative disease or condition, ischemia, reperfusion, hypoxia, atherosclerosis, ureteral obstruction, diabetes, complications of diabetes, arthritis, liver damage, insulin resistance, diabetic nephropathy, acute renal injury, chronic renal injury, acute or chronic renal injury due to exposure to nephrotoxic agents and/or radiocontrast dyes, hypertension, metabolic syndrome, an ophthalmic disease or condition such as dry eye, diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, oxygen-induced retinopathy, cardiomyopathy, ischemic heart disease, heart failure, hypertensive cardiomyopathy, vessel occlusion, vessel occlusion injury, myocardial infarction, coronary artery disease, oxidative damage.

6 . The method of claim 3 , wherein the mitochondrial dysfunction comprises mitochondrial permeability transition.

7 . The method of claim 5 , wherein the neurological or neurodegenerative disease or condition comprises Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, Huntington's disease or Multiple Sclerosis.

8 . The method of claim 3 , wherein the subject is suffering from ischemia or has an anatomic zone of no-reflow in one or more of cardiovascular tissue, skeletal muscle tissue, cerebral tissue and renal tissue.

9 . A method for reducing CD36 expression in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

10 . A method for treating or preventing a disease or condition characterized by CD36 elevation in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

11 . The method of claim 10 , wherein the subject is diagnosed as having, suspected of having, or at risk of having atherosclerosis, inflammation, abnormal angiogenesis, abnormal lipid metabolism, abnormal removal of apoptotic cells, ischemia such as cerebral ischemia and myocardial ischemia, ischemia-reperfusion, ureteral obstruction, stroke, Alzheimer's Disease, diabetes, diabetic nephropathy, or obesity.

12 . A method for reducing oxidative damage in a removed organ or tissue, comprising administering to the removed organ or tissue an effective amount of the composition of claim 1 .

13 . The method of claim 12 , wherein the removed organ comprises a heart, lung, pancreas, kidney, liver, or skin.

14 . A method for preventing the loss of dopamine-producing neurons in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

15 . The method of claim 14 , wherein the subject is diagnosed as having, suspected of having, or at risk of having Parkinson's disease or ALS.

16 . A method of reducing oxidative damage associated with a neurodegenerative disease in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

17 . The method of claim 16 , wherein the neurodegenerative disease comprises Alzheimer's disease, Parkinson's disease, or ALS.

18 . A method for preventing or treating a burn injury in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

19 . A method for treating or preventing mechanical ventiliation-induced diaphragm dysfunction in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

20 . A method for treating or preventing no reflow following ischemia-reperfusion injury in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

21 . A method for preventing norepinephrine uptake in a mammal in need of analgesia, comprising administering to the subject an effective amount of the composition of claim 1 .

22 . A method for treating or preventing drug-induced peripheral neuropathy or hyperalgesia in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

23 . A method for inhibiting or suppressing pain in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

24 . A method for treating atherosclerotic renal vascular disease (ARVD) in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

25 . The composition of claim 1 , comprising a Glp-1 analog comprising a modification selected from inclusion of one or more D-amino acids, inclusion of one or more sites of N-methylation, and inclusion of one or more reduced amide bonds (Ψ[CH 2 —NH]).

26 . The composition of claim 1 , further comprising one or more of at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent, and one or more lamination layers.

27 . The composition of claim 26 , wherein the pH-lowering agent is selected from the group consisting of citric acid, tartaric acid and, an acid salt of an amino acid.

Assignees

• Stealth Biotherapeutics Corp

Inventors

• Wilson D Travis

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title